CG 428

Indicaton

Severe Hair Loss (chemotherapy-induced, etc)

Therapeutic indications

Dermatology

Type of product

Other

Table

Phase

Phase III completed
Partnering status

Partnered
Partner

Abbott
Available in

Japan, Thailand

You may also be interested in

TOP-N53, TOP-V122, TOP-M119 and TOP-N44

TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases as chronic wounds, glaucoma, colorectal cancer, hair loss and skin aging.

Phase I started

Bimiralisib, topical [PQR309] (panPI3K/mTOR)

Non-melanoma skin cancers and rare genetic skin manifestations.

LH 7

Androgenetic Alopecia (Male & Female)

Phase II completed